Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.40 |
| ▸ | RAF1 | P04049 | 4/20 | 0.40 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | TEK | Q02763 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452154 | 0.91 | RIPK1 (0.41) | PTGESRAF1BRAFKDRTEK | |
| SCHEMBL5796359 | 0.88 | PTGES (0.40) | PTGESRAF1BRAFKDRTEK | |
| SCHEMBL5795361 | 0.79 | RIPK1 (0.41) | PTGESRAF1BRAFKDRTEK | |
| SCHEMBL5444078 | 0.75 | PTGES (0.41) | PTGESRAF1BRAFKDR | |
| SCHEMBL4164494 | 0.74 | KDR (0.59) | PTGESRAF1BRAFKDRTEK | |
| SCHEMBL5459699 | 0.74 | KDR (0.46) | RAF1BRAFKDRTEK | |
| SCHEMBL5453152 | 0.74 | KDM4E (0.46) | RAF1BRAFKDRTEK | |
| SCHEMBL5450105 | 0.73 | KDR (0.44) | PTGESRAF1BRAFKDRTEK | |
| SCHEMBL5444955 | 0.72 | KDR (0.48) | RAF1BRAFKDRTEK | |
| SCHEMBL5452188 | 0.72 | KDR (0.44) | RAF1BRAFKDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021456-A1 | Aminobenzimidazole derivatives | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021456-A1 | Aminobenzimidazole derivatives | TIE1, KDR, FLT1 | PTGES 2702/4885RAF1 17/4885BRAF 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.